Medication during enrollment.
UC
UC maintenance therapy was provided to patients during FMT. Because patients had a poor response to mesalazine, SASP, or prednisone, stable doses of drugs were used during follow-up after FMT. A subject treated with 5-ASA or SASP continued to receive the same dose of drugs administered during the study. A subject who was treated with prednisone would continue to receive it after a mandatory tapering of the dose: prednisone at >10 mg/day had a mandatory taper of 5 mg per week until the administration of 10 mg/day, and prednisone at ≤10 mg/day had a mandatory taper of 2.5 mg per week.